Framework for the Ongoing Supply of Plasmid

In response to the COVID-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. This tender is split into three lots: 1. To generate and validate a MCB for plasmid production, starting with a provided plasmid template in an appropriate strain of E. coli. 2. From the MCB, supply 10g of purified linearised plasmid manufactured according to GMP.(To simplify the tendering process, CPI will free issue the restriction enzyme for linearization to the successful bidder) 3. Provision of the combined services of Lot 1 and 2.